Form 8-K - Current report:
SEC Accession No. 0001213900-22-019512
Filing Date
2022-04-13
Accepted
2022-04-13 08:00:14
Documents
12
Period of Report
2022-04-07
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea158381-8k_actinium.htm   iXBRL 8-K 22174
  Complete submission text file 0001213900-22-019512.txt   195283

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE atnm-20220407.xsd EX-101.SCH 3051
3 XBRL LABEL FILE atnm-20220407_lab.xml EX-101.LAB 34476
4 XBRL PRESENTATION FILE atnm-20220407_pre.xml EX-101.PRE 22607
6 EXTRACTED XBRL INSTANCE DOCUMENT ea158381-8k_actinium_htm.xml XML 3610
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36374 | Film No.: 22823675
SIC: 2834 Pharmaceutical Preparations